Vericel Corp (VCEL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine and severe burn care. Its primary products include MACI (cartilage repair), Epicel (skin replacement for burns), and NexoBrid (eschar removal for burns). The company operates in a single reportable segment and is headquartered in Cambridge, Massachusetts.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenue | $115,838 |
| Gross Profit | $82,886 |
| Gross Margin | 71.6% |
| Net Loss | $(11,799) |
| Net Loss Per Share (Diluted) | $(0.24) |
| Operating Cash Flow | $14,814 |
| Cash and Cash Equivalents | $80,532 |
| Total Investments (Short & Long-term) | $83,749 |
| Total Debt | $0 (No outstanding borrowings) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 11.4% to $115.8 million compared to $103.9 million in the prior year period. This was driven by an 18.3% increase in MACI revenue and a 107.9% increase in NexoBrid revenue, partially offset by a 26.3% decline in Epicel revenue.
- Profitability: The net loss widened by 38.1% to $11.8 million from $8.5 million in the prior year, primarily due to a 20.2% increase in Selling, General, and Administrative (SG&A) expenses.
- Expense Trends: SG&A expenses rose to $83.7 million (from $69.7 million) due to higher headcount, stock-based compensation, marketing programs, and depreciation related to the new Burlington, Massachusetts facility. R&D expenses remained relatively flat, increasing slightly by 1.5%.
- Liquidity: Operating cash flow decreased to $14.8 million from $25.7 million in the prior year, largely due to a net decrease in working capital (increased accounts receivable and decreased accounts payable/accrued expenses).
Guidance, Outlook, and Risks
- Outlook: Management expects current cash, investments, and borrowing capacity to support operations for at least 12 months. The company is expanding its target surgeon base for MACI to 7,000 following the FDA approval of the arthroscopic delivery method (MACI Arthro) in August 2024.
- Product Pipeline: The company plans to initiate a clinical trial for MACI Ankle in 2025 to expand indications to ankle cartilage defects.
- Key Risks:
- Geopolitical: Ongoing conflicts in the Middle East involving Israel pose a risk to the supply chain for NexoBrid, which is manufactured by MediWound in Israel. The company currently maintains ample U.S. inventory.
- Regulatory: Potential disruptions at the FDA due to government funding issues, staffing changes, or policy shifts under the new administration could delay product approvals or facility qualifications.
- Reimbursement: Revenue recognition relies on estimates of third-party payer reimbursements; changes in these estimates can materially impact reported revenue.
Investor Verification Checklist
- Verify the sustainability of MACI revenue growth following the launch of the arthroscopic delivery method.
- Monitor the impact of geopolitical instability in Israel on NexoBrid supply and potential cost increases.
- Assess the trajectory of SG&A expenses relative to revenue growth, particularly regarding the new Burlington facility costs.
- Review the timeline and progress of the planned MACI Ankle clinical trial.
- Confirm the company's ability to maintain liquidity without additional capital raises given the widening net loss.